0       0

Satellite Symposium: Interpreting Therapeutic Advancements


Interpreting Therapeutic Advancements and Addressing Clinical Challenges in Heart Failure Management


Description

CLICK HERE TO START ACTIVITY

Date of Release: December 1, 2016
Program End Date: November 30, 2017

PROGRAM DESCRIPTION
Heart failure (HF) affects an estimated 5.7 million individuals in the United States, with an incidence of 915,000 new cases per year. Because management of HF remains a challenge for many clinicians, the goal of this program is to educate cardiologists and other HF specialists on the appropriate use of current and evolving treatment options for HF, thereby improving their abilities to implement individualized treatment strategies, promote shared decision-making with their patients and, ultimately, enhance patient quality of life. Through presentations and open discussion, expert faculty discuss issues surrounding the identification of common challenges and evolving strategies in the management of patients with HF; assessment of the safety and efficacy of available treatment options for HF; and evaluation of the latest and emerging clinical trial data regarding novel treatment options. Recognizing risk factors for suboptimal outcomes; selecting and initiating appropriate medications; individualizing treatment, education, and post-discharge self-care; and adopting a multidisciplinary approach to management can help patients with HF and help clinicians improve health outcomes.

INTENDED AUDIENCE
Cardiologists, internists, nurse practitioners (NPs), physician assistants (PAs), nurses, and other clinicians who manage patients with heart failure

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be better able to:

  • Summarize the mechanisms of action and different clinical attributes of established, newly approved, and investigational therapies for the management of heart failure (HF)
  • Evaluate methods for individualizing chronic HF treatment strategies for patients based on reduced and preserved ejection fraction HF and other patient-related factors
  • Analyze processes to reduce hospitalization and readmission that include reinforcing nonpharmacologic and pharmacologic treatment adherence, providing appropriate discharge instructions, and adopting a collaborative team-based approach to patient care
  • Assess approaches for employing quality-improvement strategies, such as patient education and engagement, to involve patients in self-management and monitoring of their HF syndrome

FACULTY DISCLOSURES
Mona Fiuzat, PharmD, FACC, FHFSA - has nothing to disclose.

Mark E. Dunlap, MD - has nothing to disclose.

Scott D. Solomon, MD - receives research grants from Alnylam Pharmaceuticals, Amgen, AstraZeneca, Ionis Pharmaceuticals, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, and Sanofi. He is also a consultant for and an advisory board member of Amgen, AstraZeneca, Bristol-Myers Squibb, Cytokinetics Inc., GlaxoSmithKline, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.

John R. Teerlink, MD, FHFSA, FACC, FAHA, FESC, FRCP - receives research grants from Amgen, Bayer, Bristol-Myers Squibb, Cardio3 Biosciences (now Celyad S.A.), Medtronic, and Novartis Pharmaceuticals Corporation. He is also a consultant for and an advisory board member of Amgen, Bayer, Bristol-Myers Squibb, Cytokinetics Inc., Mast Therapeutics, Novartis Pharmaceuticals Corporation, Relypsa Inc., and ZS Pharma.

ACCREDITED PROVIDER DISCLOSURES
Heart Failure Society of America Satellite Symposium Review Committee Disclosures

Gregg Fonarow, MD, receives research grants from the National Institutes of Health (NIH). He is also a consultant for and an advisory board member of Amgen, Janssen, Medtronic, Novartis Pharmaceuticals Corporation, St. Jude Children’s Research Hospital, and ZS Pharma.

Kenneth Margulies, MD, receives research grants from CardioCell LLC, Merck Sharp & Dohme Corp., and St. Luke’s Hospital (Kansas City, MO). He is also a consultant for and an advisory board member of GlaxoSmithKline, Janssen Pharmaceuticals, and Merck Sharp & Dohme Corp

Marc Semigran, MD, receives research grants from CVRx, Inc., St. Jude Children’s Research Hospital, and Novartis Pharmaceuticals Corporation. He is also a consultant for and an advisory board member of Amgen and Broadview Ventures, Inc.

John Burnett, Jr, MD; Debra Moser, DNSc, RN; David Wehellan, MD; and Jaime Abreu, MBA; (staff) have nothing to disclose.

PUBLISHING STAFF DISCLOSURES
Marcello Morgan, MD, and Lori Marrese of Haymarket Medical Education have nothing to disclose.

CREDIT
2.00

TYPE
AMA PRA Category 1 Credit(s)TM

ACCREDITATION STATEMENT
The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION STATEMENT
The Heart Failure Society of America designates this enduring activity for a maximum of 2.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE OF UNLABELED USE
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Heart Failure Society of America, Haymarket Medical Education, and the Novartis Pharmaceuticals Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

INSTRUCTIONS
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any CME questions, please email the HFSA at info@hfsa.org

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

PRIVACY POLICY
myCME privacy policy

Speaker(s):

  • Mark Dunlap, MD, Metro Health System
  • Mona Fiuzat, PharmD, Adjunct Associate Professor, Food and Drug Administration (FDA)/Duke University
  • Scott Solomon, MD, Director, Noninvasive Cardiology, Brigham and Women's Hospital 
  • John Teerlink, MD, Professor of Medicine, San Francisco VAMC

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content